🇺🇸 FDA
Pipeline program

Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066

M15-998

Phase 3 small_molecule active

Quick answer

Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066 for Psoriatic Arthritis is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Psoriatic Arthritis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials